Gene therapy is a promising strategy for treating patients suffering from X-linked Chronic Granulomatous Disease.
A two-year NIH grant to JAX totaling $455,000 will support research to improve the accuracy and efficiency of CRISPR-Cas9 genome editing.
Caribou has granted JAX non-exclusive worldwide rights to use its CRISPR-Cas9 intellectual property to create genetically engineered mice for research purposes.
The National Institutes of Health (NIH) will award a total of $28,305,235 to The Jackson Laboratory (JAX) over five years to fund phase 2 of the Knockout Mouse Production and Phenotyping Project (KOMP2).
Learn how three powerful CRISPR/Cas9 approaches work to edit mouse genomes and generate pre-clinical models for developing and validating therapies for human diseases.
You’ve made a mutation using CRISPR/Cas9 Now what?
The Jackson Laboratory has obtained patent licenses from both The Broad Institute and Caribou Biosciences to provide customers with rights under patents covering the CRISPR Cas9 process to use new mouse models created at JAX with CRISPR-Cas9 for most internal research. Thus, no matter which of the two parties wins the high profile, high stakes dispute over who owns patent rights to the genome editing technology, JAX customers will be protected.
Comprehensive suite of genome editing technologies will enable custom-made mouse models for studying human disease.
A cure for HIV seems unlikely until we find efficient ways to evict latent viral DNA camouflaged in patients’ own genomes. Researchers are using CRISPR strategies to protect the immune system from relentless HIV attacks and also to carefully eradicate their dormant viruses.
A new gene regulation and labeling platform dubbed "Casilio" is expanding researchers' ability to study gene function and chromosome structure.